Janus kinase signaling activation mediates peritoneal inflammation and injury in vitro and in vivo in response to dialysate

Kidney International

Volumn 86, Issue 6, 2014, Pages 1187-1196

  Dai, Tiane ^a   Wang, Ying ^a   Nayak, Aditi ^a   Nast, Cynthia C ^b   Quang, Lan ^a   Lapage, Janine ^a   Andalibi, Ali ^a   Adler, Sharon G ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

JAK inhibitor; JAK STAT; MCP 1; Periostin; Peritoneal dialysis

Indexed keywords

CASPASE 3; DIANEAL; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; RUXOLITINIB; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR RUNX2; CCL2 PROTEIN, HUMAN; CCL2 PROTEIN, RAT; CELL ADHESION MOLECULE; DIALYSIS FLUID; POSTN PROTEIN, HUMAN; POSTN PROTEIN, RAT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MESOTHELIUM CELL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEAL INJURY; PERITONITIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; TREATMENT OUTCOME; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; EPITHELIUM CELL; HYPERPLASIA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERITONEUM; PHOSPHORYLATION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TIME; VASCULARIZATION;

ANIMALS; CASPASE 3; CELL ADHESION MOLECULES; CELLS, CULTURED; CHEMOKINE CCL2; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; FEMALE; HUMANS; HYPERPLASIA; JANUS KINASES; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; RATS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS;

EID: 84926182217     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.209     Document Type: Article

References (87)

1. Tokgoz B. Clinical advantages of peritoneal dialysis. Perit Dial Int 2009; 29(Suppl 2): S59-S61.
2. Fenton SS, Schaubel DE, Desmeules M et al. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30: 334-342.
3. Heaf JG, L-kkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002; 17: 112-117.
4. Termorshuizen F, Korevaar JC, Dekker FW et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: Analysis of the Netherlands Cooperative Study on theAdequacy of Dialysis 2. J Am Soc Nephrol 2003; 14: 2851-2860.
5. Barendse SM, Speight J, Bradley C. The Renal TreatmentSatisfaction Questionnaire (RTSQ): A measure of satisfaction with treatment for chronic kidney failure. Am J Kidney Dis 2005; 45: 572-579.
6. Rubin HR, Fink NE, Plantinga LC et al. Patient ratings of dialysis care with peritoneal dialysis vs. hemodialysis. JAMA 2004; 291: 697-703.
7. Juergensen E, Wuerth D, Finkelstein SH et al. Hemodialysis and peritoneal dialysis: patients' assessment of their satisfaction with the therapy and the impact of the therapy on their lives. Clin J Am Soc Nephrol 2006; 1: 1191-1196.
8. Churchill DN, Taylor DW, Keshaviah PR et al. Adequacy of dialysis andnutrition in continuous peritoneal dialysis: Associationwith clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207.
9. Misra M, Vonesh E, Van Stone JC et al. Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59: 754-763.
10. Lang SM, Bergner A, Tö pfer M et al. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001; 21: 52-57.
11. Van Biesen W, Veys N, Vanholder R et al. The impact of the pre-transplant renal replacement modality on outcome after cadaveric kidney transplantation: the Ghent experience. Contrib Nephrol 2006; 150: 254-258.
12. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD et al. The role of pretransplantation renal replacement therapy modality in kidney allograf t and recipient survival. Am J Kidney Dis 2005; 46: 537-549.
13. Pérez Fontán M, Rodríguez-Carmona A, Bouza P et al. Delayed graft function after renal transplantation in patients undergoing peritoneal dialysis and hemodialysis. Adv Perit Dial 1996; 12: 101-104.
14. Snyder JJ, Foley RN, Gilbertson DT et al. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15: 174-179.
15. Gokal R, King J, Bogle S et al. Outcome in patients on continuous ambulatory peritoneal dialysis and hemodialysis: 4-year analysis of a prospective multicentre study. Lancet 1987; 330: 1105-1109.
16. Serkes KD, Blagg CR, Nolph KD et al. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: A multicenter study. Perit Dial Int 1990; 10: 15-19.
17. Maiorca R, Cancarini GC, Zubani R et al. CAPD viability: A long-term comparison with hemodialysis. Perit Dial Int 1996; 16: 276-287.
18. Gokal R. Peritoneal dialysis in the 21st century: An analysis of current problems and future developments. J Am Soc Nephrol 2002; 13(Suppl 1): S104-S115.
19. Kawaguchi Y. Peritoneal dialysis as long-term treatment: comparison of technique survival between Asian and Western populations. Perit Dial Int 1999; 19(Suppl 2): S327-S328.
20. Schilte MN, Celie JW, Wee PM et al. Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int. 2009; 29: 605-617.
21. Albrektsson A, Bazargani F, Wieslander A et al. Peritoneal dialysis fluidinduced angiogenesis in rat mesentery is increased by lactate in the presence or absence of glucose. ASAIO J 2006; 52: 276-281.
22. Zareie M, Hekking LH, Welten AG et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629-2637.
23. Hekking LHP, Zareie M, Driesprong BAJ et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12: 2775-2786.
24. Witowski J, Korybalska K, Wisniewska J et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729-739.
25. De Vriese AS, Flyvbjerg A, Mortier S et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14: 2109-2118.
26. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207.
27. Boulanger E, Grossin N, Wautier MP et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2006; 71: 126-133.
28. Boulanger E, Wautier M-P, Wautier J-L et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-156.
29. Flessner MF, Credit K, Henderson K et al. Peritoneal changes after exposure to sterile solutions by catheter. J Am Soc Nephrol. 2007; 18: 2294-2302.
30. Flessner MF, Credit K, Richardson K et al. Peritoneal inflammation after twenty-week exposure to dialysis solution: effect of solution versus catheter-foreign body reaction. Perit Dial Int 2010; 30: 284-293.
31. Verger C, Luger A, Moore HL et al. Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. Kidney Int 1983; 23: 823-831.
32. Zareie M, De Vriese AS, Hekking LH et al. Immunopathological changes in a uraemic rat model for peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 1350-1361.
33. Yanez-Mo M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelialto-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-413.
34. Schilte MN, Loureiro J, Keuning ED et al. Long-term intervention with heparins in a rat model for peritoneal dialysis. Perit Dial Int 2009; 29: 26-35.
35. Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediat Nephrol 2008; 23: 19-25.
36. Zareie M, Keuning ED, Wee PM et al. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 2006; 21: 208-216.
37. Di Paolo N, Sacchi G, Garosi G et al. Omental milky spots and peritoneal dialysis-review and personal experience. Perit Dial Int 2005; 25: 48-57.
38. Williams JD, Craig KJ, Ruhland CV et al. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int 2003; 64(Suppl 88): S43-S49.
39. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
40. Liang Y, Sasaki K. Expression of adhesion molecules relevant to leukocyte migration on the microvilli of liver peritoneal mesothelial cells. Anat Rec 2000; 258: 39-46.
41. Xu ZG, Kim KS, Park HC et al. High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells. Kidney Int 2003; 63: 958-968.
42. Lee HB, Yu MR, Song JS et al. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004; 65: 1170-1179.
43. Schwenger V. GDP and AGE receptors: mechanisms of peritoneal damage. Contrib Nephrol 2006; 150: 77-83.
44. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005; 18: 243-249.
45. Lai KN, Tang SC, Leung JC. Mediators of inflammation and fibrosis. Perit Dial Int 2007; 27(Suppl 2): S65-S71.
46. Leung JC, Chan LY, Tang SC et al. Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 2006; 69: 2078-2086.
47. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117: 1281-1283.
48. Amiri F, Shaw S, Wang X et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002; 61: 1605-1616.
49. Huang JS, Guh JY, Chen HC et al. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-113.
50. Himmele R, Sawin DA, Diaz-Buxo JA. GDPs and AGEs: impact on cardiovascular toxicity in dialysis patients. Adv Perit Dial 2011; 27: 22-26.
51. Jonasson P, Braide M. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages. Perit Dial Int 1998; 18: 376-381.
52. Jonasson P, Braide M. Kinetics and dose response of the effects of heated glucose peritoneal dialysis fluids on the respiratory burst of rat peritoneal leukocytes. ASAIO J 2000; 46: 469-473.
53. Witowski J, Topley N, Jö rres A et al. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47: 282-293.
54. Bos EN, van Bronswijk H, Helmerhorst TJM et al. Distinct populations of elicited human macrophages in peritoneal dialysis patients and women undergoing laparoscope. A study of peroxidatic activity. J Leukocyte Biol 1988; 43: 172-178.
55. Baroni G, Schuinski A, de Moraes TP et al. Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis. Mediators Inflamm 2012; 2012: 912595.
56. Lambie M, Chess J, Donovan KL et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24: 2071-2080.
57. Robson RL, McLoughlin RM, Witowski J et al. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo. J Immunol 2001; 167: 1028-1038.
58. Hausmann MJ, Rogachev B, Weiler M et al. Accessory role of human peritoneal mesothelial cells in antigen presentation and T-cell growth. Kidney Int 2000; 57: 476-486.
59. Satirapoj B, Wang Y, Chamberlin MP et al. Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant 2012; 27: 2702-2711.
60. Yan W, Shao R. Transduction if a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial to mesenchymal transformation. J Biol Chem 2006; 281: 19700-19708.
61. Hamilton DW. Functional role of periostin in development and wound repair: implications for connective tissue disease. J Cell Commun Signal 2008; 2: 9-17.
62. Braun N, Sen K, Alscher MD et al. Periostin: A matricellular protein involved in peritoneal injury during peritoneal dialysis. Perit Dial Int 2013; 33: 515-528.
63. Tekstra J, Visser CE, Tuk CW et al. Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2379-2384.
64. Visser CE, Tekstra J, Brouwer-Steenbergen JJ et al. Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol 1998; 112: 270-275.
65. Berthier CC, Zhang H, Schin M et al. Enhanced expression of Janus kinasesignal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477.
66. Tesch GH. MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697-F701.
67. Arbeiter K, Bidmon B, Endemann M et al. Peritoneal dialysate fluid composition determines heat shock protein expression patterns in human mesothelial cells. Kidney Int 2001; 60: 1930-1937.
68. Chan TM, Leung JK, Tsang RC et al. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64: 519-533.
69. Bidmon B, Endemann M, Arbeiter K et al. Overexpression of HSP-72 confers cytoprotection in experimental peritoneal dialysis. Kidney Int 2004; 66: 2300-2307.
70. Kinashi H, Ito Y, Mizuno M et al. TGF-b1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol 2013; 24: 1627-1642.
71. Kratochwill K, Boehm M, Herzog R et al. Alanyl-glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids. Nephrol Dial Transplant 2012; 27: 937-946.
72. Washida N, Wakino S, Tonozuka Y et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant 2011; 26: 2770-2779.
73. Ogata R, Hiramatsu N, Hayakawa K et al. Impairment of MCP-1 expression in mesothelial cells exposed to peritoneal dialysis fluid by osmotic stress and acidic stress. Perit Dial Int 2011; 31: 80-89.
74. Strippoli R, Benedicto I, Foronda M et al. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-tomesenchymal transition. J Cell Sci 2010; 123: 4321-4331.
75. Kratochwill K, Lechner M, Siehs C et al. Stress responses and conditioning effects in mesothelial cells exposed to peritoneal dialysis fluid. J Proteome Res 2009; 8: 1731-1747.
76. Endemann M, Bergmeister H, Bidmon B et al. Evidence for HSP-mediated cytoskeletal stabilization in mesothelial cells during acute experimental peritoneal dialysis. Am J Physiol Renal Physiol 2007; 292: F47-F56.
77. Yung S, Li FK, Chan TM. Peritoneal mesothelial cell culture and biology. Perit Dial Int 2006; 26: 162-173.
78. Murphy JE, Rheinwald JG. Intraperitoneal injection of genetically modified, human mesothelial cells forsystemic gene therapy. Hum Gene Ther 1997; 8: 1867-1879.
79. Pecoits-Filho R, Araú jo MR, Lindholm B et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17: 1480-1486.
80. Oh KH, Jung JY, Yoon MO et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25: 1639-1646.
81. Johnson DW, Brown FG, Clarke M et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23: 1097-1107.
82. Gotloib L, Wajsbrot V, Shostak A. Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin. Nephron 2002; 92: 142-155.
83. Moriishi M, Kawanishi H, Watanabe H et al. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv Perit Dial 2005; 21: 21-24.
84. Cho Y, Badve SV, Hawley CM et al. Biocompatible peritoneal dialysis fluids: clinical outcomes. Int J Nephrol 2012; 2012: 812609.
85. Srivastava S, Hildebrand S, Fan SL. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney Int 2011; 80: 986-991.
86. Fielding CA, Jones GW, McLoughlin RM et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014; 40: 40-50.
87. Dai T, Natarajan R, Nast CC et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 2006; 6: 806-814.